HIV Antivirals Market Outlook (2022-2032)

[300 Pages Report] The global HIV antivirals market is set to reach a valuation of US$ 30.6 Billion in 2022, and register a CAGR of 4.4% during the forecast period (2022 to 2032). According to a recent study, fixed-dose combinations (FDCs) are leading the HIV antivirals market with a share of over 83% in 2021.

Market Outlook:

Data Points Market Insights
HIV Antivirals Market Value 2021 US$ 29.4 Billion
Market Value 2022 US$ 30.6 Billion
Market Value 2032 US$ 47.0 Billion
CAGR 2022 to 2032 4.4%
Market Share of Top 5 Countries 64.8%

The demand for HIV antivirals is projected to surge with increasing access to effective HIV diagnosis, treatment, prevention, and care. It makes HIV infection a manageable chronic health condition such as cancer and tuberculosis, which enables people living with HIV to lead healthy and long lives.

The HIV antivirals market is poised to expand on the back of rising awareness about HIV causes, symptoms, and available treatment options. There are various awareness programs organized by the U.S. Department of Health & Human Services for creating awareness regarding HIV and its testing.

For instance, the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) observe the day 18th May as HIV Vaccine Awareness Day. This is to show gratitude towards the community members, volunteers, healthcare professionals, and scientists working together to find a safe and effective preventive HIV vaccine.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Sales Analysis of HIV Antivirals Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032

Overall sales of HIV antivirals expanded at a CAGR of 4.0% from 2017 to 2021 owing to the rise in various government and NGO plans to offer greater accessibility to disease diagnosis and treatment for infected persons. As per Future Market Insights (FMI), the demand for HIV antivirals was approximately 66.5%, totalling US$ 44.2 Bn of the global antiviral drugs market in 2021.

For instance, the International AIDS Society (IAS) is the world’s largest association of HIV professionals from more than 170 countries. It plays a vital role in improving the lives of people with and most vulnerable to acquiring HIV by promoting the implementation of evidence-informed and human rights-based strategies.

Rising initiatives by government across the globe and NGOs is expected to boost the HIV antiviral market. Hence, key players operating in the market are capitalizing on this existing trend by launching new products.

For instance, in January 2021, ViiV Healthcare gained marketing authorization from European Commission for Tivicay (dolutegravir) for the treatment of human immunodeficiency virus (HIV-1) infection in pediatric patients.

In addition, increasing awareness about the available treatments to control HIV growth is also enhancing the demand for the HIV antivirals market.  

HIV Antivirals Market

What are the Key Opportunities for Manufacturers in the HIV Antivirals Market?

Key manufacturers in HIV antivirals market are actively participating in clinical trials for the development of HIV antivirals. For instance, ViiV Healthcare is sponsoring “the study to evaluate the antiviral effect, safety and tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 infected adults”, which is currently in phase 2.

Similarly, the National Institute of Allergy and Infectious Diseases (NIAID) is also sponsoring a project named “Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents”, which is currently in phase 2. On the back of these developments, the demand in the HIV antivirals market is expected to propel over the assessment period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Factors Restraining the Demand in HIV Antivirals Market?

 The market is being impacted by limited access to HIV treatment and a lack of awareness in emerging nations. One-fifth of the urban population is HIV-positive and unaware of it. Increased HIV testing among the general population could be one way for regional and national planning actions to address this issue.

Rigorous government guidelines for the approval and commercialization of HIV drugs is also creating a hurdle for the growth of the market by limiting the number of drugs launched every year for HIV. Thus, it is harming the overall market growth.

Additionally, the lack of advanced infrastructure and limited facilities for screening and testing may limit the population with HIV infection to opt for proper treatment.

Furthermore, a large number of under-diagnosed populations is increasing due to a lack of adequate data to guide country-specific testing approaches, lack of guidelines on testing for resource-limited settings, and stigmatization of populations with or at high risk of infection.

Country-wise Insights

What Makes the U.S. the Largest Market for HIV Antivirals?

Availability of Funded Drug Assistance Programs in the U.S. to Propel Growth in HIV Antivirals Market

The U.S. dominated the North America HIV antivirals market with a total market share of around 96.8% in 2021. Demand for HIV antivirals is expected to surge due to the presence of various federally funded assistance programs in the country.

For instance, the AIDS Drug Assistance Program (ADAP) helps people with less income pay for HIV and AIDS medications. In many states, it covers extra costs such as prescription drugs and lab tests that are not for treating HIV/AIDS.

Thus, U.S. market will have a great opportunity in the region for growth, due to better assistance programs in the approaching years.

Why is the U.K. Considered a Lucrative HIV Antivirals Market in Europe?

Favorable Government and NGO Policies to Boost the U.K. HIV Antivirals Market

As per FMI, the U.K. is set to exhibit a CAGR of nearly 4.3% in the Europe HIV antivirals market during the forecast period. Government in the U.K. provides all HIV treatment free for the residents in the country, regardless of their immigration status. These kinds of facilities aid the middle and low-income population to take the best treatment for HIV.

Moreover, the approval for the use of injectable treatment using a combination of cabotegravir with rilpivirine instead of oral antiretroviral is a better treatment option for HIV patients. This is due to the dosing frequency of injectable is much lower than the oral dosage.

Will China Emerge as a Remunerative HIV Antivirals Market in East Asia?

Rising Prevalence of HIV to Improve the Demand for HIV Vaccine Boosting China HIV Antivirals Market

China held more than 75% share in the East Asia HIV antivirals market in 2021 and is projected to increase at a CAGR of 4.4% during the forecast period. Demand in the market is projected to surge on the back of rising prevalence of HIV in China.

For instance, according to studies published in NCBI, approximately 1.1 million people were living with HIV in 2020 in China. The demand for HIV antivirals is increasing with the growing rate of infection to treat or manage the disease.

How Big is the India HIV Antivirals Market?

Demand for HIV Drugs to Surge in India Amid Growing Cases of HIV and Rising Infant Mortality Rate

India held around 45.3% share in South Asia HIV antivirals market in 2021 and is projected to register a CAGR of 4.8% during the forecast period. Growth is primarily due to the high infant mortality rate and presence of HIV cases in the country.

Further, presence of awareness programs in the country, such as the National Aids Control Programme, is a key factor accelerating the demand in the market. It is a centrally sponsored scheme run by the Ministry of Health and Family Welfare of the Government of India with the goal of halving new HIV/AIDS infections and providing comprehensive care, support, and treatment to all HIV/AIDS patients.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

Which Product Will Account for Lion’s Share in HIV Antivirals Market?

Fixed Dose Combinations (FDCs) to Account for Over 4/5th of HIV Antivirals Sales

Fixed dose combinations (FDCs) held a market share of around 83.2% in 2021 and is estimated to witness growth at a CAGR of 4.5% during the forecast period.

High demand for FDCs drugs is due to the simplicity of the regimen, drug-drug interactions, and infrequent adverse effects in combination with a low pill burden. It also prevents the virus to reproduce by restricting an enzyme HIV needs to make copies of itself.

Thus, FDCs drugs help to improve adherence to an HIV treatment regimen which drives the demand for FDCs in forthcoming years.

Which is the Leading Sales Channel in the HIV Antivirals Market?

Sales of HIV Antivirals in Hospital Pharmacies to Surge at a Robust Pace

The hospital pharmacies segment held a market share of 53.4% in 2021 and is expected to hold a share of over 54.0% in 2032.

Increasing number of people seeking treatment in hospitals are purchasing the drugs through hospital pharmacies. This is due to factors such as easy availability and subsidized prices. Thus, hospital pharmacies help in increasing the sale of HIV antiviral drugs and will drive the HIV antivirals market.

Competitive Landscape

Key players in the HIV antivirals market are concentrating on collaborations and gaining FDA approvals, as the key strategies for expanding their business in the market.

These factors will support the market players, such as Theratechnologies and AbbVie, to improve their product portfolio together with market penetration, thus, increasing their revenue share in the global market.

For instance:

  • In December 2021, Theratechnologies announced the submission of a license application for supplemental biologics to FDA for advancing the development of IV Push Trogarzo® for patients living with HIV.
  • • In March 2020, AbbVie announced a partnership with international authorities to test the efficacy of HIV medicines in treating COVID-19.

Report Scope as per HIV Antivirals Market Analysis

Attributes Details
Market Value 2022 US$ 30.6 Billion
Market Value 2032 US$ 47.0 Billion
CAGR 2022-2032 4.4%
Forecast Period 2017 to 2021
Historical Data Available for 2022 to 2032
Market Analysis US$ Million for Value
Key Regions Covered North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa
Key Countries Covered USA, China, Japan, Germany, Canada, UK, India, South Korea, Russia, Australia, BENELUX, Spain, Indonesia, France, Italy, Brazil, Thailand, Malaysia, Vietnam, Philippines, Mexico, GCC Countries, Argentina, South Africa, North Africa, Turkey, and New Zealand
Key Market Segments Covered Product, Sales Channel, and Region
Key Companies Profiled
  • ViiV Healthcare
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Johnson & Johnson
  • Genetech, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie
  • Cipla
  • Pfizer Inc.
  • Mylan N.V.
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Macleods Pharmaceuticals Ltd
  • Emcure Pharmaceuticals Limited
  • Aspen Pharmacare Limited
  • Lupin Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Strides Arcolab Limited
  • Hetero labs limited
  • Laurus Laboratories Ltd

Key Market Segments Covered in HIV Antivirals Market Research

By Product:

  • Fixed Dose Combinations (FDCs)
  • Integrase Strand Transfer Inhibitors (INSTIs)
  • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Entry Inhibitors - CCR5 co-receptor antagonist
  • Protease Inhibitors (PIs)
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Others

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

How much is the HIV antivirals market worth in 2021?

The global HIV antivirals market is worth US$ 29.4 Bn in 2021 and is set to expand 1.5X over the next ten years.

What is the sales forecast for HIV antivirals through 2032?

The HIV antivirals market is expected to reach US$ 47.0 Bn by the end of 2032, with sales revenue expected to register a 4.4% CAGR over the forecast period (2022-2032).

What are the key trends shaping the HIV antivirals market?

Increasing research and development activities to develop long-acting antiviral therapies, the rising number of clinical trials, and the increasing number of product launches, are some of the key trends in this market.

Which are the top 5 countries driving demand for HIV antivirals market?

The U.S., Germany, India, China, and the U.K. are expected to drive demand for the HIV antivirals industry.

What is the North America market outlook for HIV antivirals?

North America is one of the key markets for HIV antivirals and the U.S. is accounting for around 96.8% of the North American market in the year 2021.

At what percentage is the demand for HIV antivirals expected to register growth in Europe?

The demand for HIV antivirals in Europe is expected to register a growth of 4.1% over the next ten years.

Table of Content
1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand Side Trends
    1.3. Supply-Side Trends
    1.4. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
    2.3. Inclusions and Exclusions
3. Key Market Trends
    3.1. Key Trends Impacting the Market
    3.2. Product Innovation / Development Trends
4. Key Success Factors
    4.1. HIV Disease Epidemiology 
    4.2. Regulatory Scenario
    4.3. Clinical Pipeline Assessment
    4.4. PESTLE Analysis 
    4.5. Porters Analysis 
    4.6. Key Promotional Strategies by Key Manufacturers 
5. Market Background
    5.1. Macro-Economic Factors
        5.1.1. Global GDP Growth Outlook
        5.1.2. Global Healthcare Spending Outlook
        5.1.3. Global Antiviral Drugs Market Outlook
    5.2. Forecast Factors - Relevance & Impact
        5.2.1. Increasing Incidence of HIV Infection
        5.2.2. Demand for HIV Medications
        5.2.3. Rise in Research & Development Activities
        5.2.4. Increase in Drug Approvals
        5.2.5. Rising Awareness Among People
        5.2.6. Rise in Use of Antivirals
        5.2.7. Strategical Mergers and Acquisitions Among Key Players
    5.3. Market Dynamics
        5.3.1. Drivers
        5.3.2. Restraints
        5.3.3. Opportunity Analysis
6. COVID19 Crisis Analysis
    6.1. COVID19 and Impact Analysis
        6.1.1. Revenue By Product
        6.1.2. Revenue By Sales Channel
        6.1.3. Revenue By Country
    6.2. 2021 Market Scenario
7. Global HIV Antivirals Market Demand (in Value or Size in US$ Mn) Analysis 2012–2021 and Forecast, 2022–2032
    7.1. Historical Market Value (US$ Mn) Analysis, 2012–2021
    7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032
        7.2.1. Y-o-Y Growth Trend Analysis
        7.2.2. Absolute $ Opportunity Analysis
8. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Product 
    8.1. Introduction / Key Findings
    8.2. Historical Market Size (US$ Mn), By Product, 2012–2021
    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032
        8.3.1. Fixed Dose Combinations (FDCs)
        8.3.2. Integrase Strand Transfer Inhibitors (INSTIs)
        8.3.3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
        8.3.4. Entry Inhibitors - CCR5 co-receptor antagonist
        8.3.5. Protease Inhibitors (PIs)
        8.3.6. Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
        8.3.7. Others
    8.4. Market Attractiveness Analysis By Product 
9. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Sales Channel 
    9.1. Introduction / Key Findings
    9.2. Historical Market Size (US$ Mn), By Sales Channel, 2012–2021
    9.3. Current and Future Market Size (US$ Mn) and Forecast By Sales Channel, 2022–2032
        9.3.1. Hospital Pharmacies
        9.3.2. Retail Pharmacies
        9.3.3. Online Pharmacies
    9.4. Market Attractiveness Analysis By Sales Channel
10. Global HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032, by Region
    10.1. Introduction
    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2021
    10.3. Current and Future Market Size (US$ Mn) and Forecast By Region, 2022–2032
        10.3.1. North America
        10.3.2. Latin America
        10.3.3. Europe
        10.3.4. East Asia
        10.3.5. South Asia
        10.3.6. Oceania
        10.3.7. Middle East and Africa (MEA)
    10.4. Market Attractiveness Analysis By Region
11. North America HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032
    11.1. Introduction
    11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        11.3.1. By Country
            11.3.1.1. U.S.
            11.3.1.2. Canada
        11.3.2. By Product
        11.3.3. By Sales Channel
    11.4. Market Attractiveness Analysis
        11.4.1. By Country
        11.4.2. By Product
        11.4.3. By Sales Channel
    11.5. Market Trends
    11.6. Key Market Participants - Intensity Mapping
    11.7. Drivers and Restraints - Impact Analysis
    11.8. Country Level Analysis & Forecast
        11.8.1. U.S. HIV Antivirals Market Analysis
            11.8.1.1. Introduction
            11.8.1.2. Market Analysis and Forecast by Market Taxonomy
                11.8.1.2.1. By Product
                11.8.1.2.2. By Sales Channel
        11.8.2. Canada HIV Antivirals Market Analysis
            11.8.2.1. Introduction
            11.8.2.2. Market Analysis and Forecast by Market Taxonomy
                11.8.2.2.1. By Product
                11.8.2.2.2. By Sales Channel
12. Latin America HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032
    12.1. Introduction
    12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        12.3.1. By Country
            12.3.1.1. Mexico
            12.3.1.2. Brazil
            12.3.1.3. Argentina
            12.3.1.4. Rest of Latin America
        12.3.2. By Product
        12.3.3. By Sales Channel
    12.4. Market Attractiveness Analysis
        12.4.1. By Country
        12.4.2. By Product
        12.4.3. By Sales Channel
    12.5. Market Trends
    12.6. Key Market Participants - Intensity Mapping
    12.7. Drivers and Restraints - Impact Analysis
    12.8. Country Level Analysis & Forecast
        12.8.1. Mexico HIV Antivirals Market Analysis
            12.8.1.1. Introduction
            12.8.1.2. Market Analysis and Forecast by Market Taxonomy
                12.8.1.2.1. By Product
                12.8.1.2.2. By Sales Channel
        12.8.2. Brazil HIV Antivirals Market Analysis
            12.8.2.1. Introduction
            12.8.2.2. Market Analysis and Forecast by Market Taxonomy
                12.8.2.2.1. By Product
                12.8.2.2.2. By Sales Channel
        12.8.3. Argentina HIV Antivirals Market Analysis
            12.8.3.1. Introduction
            12.8.3.2. Market Analysis and Forecast by Market Taxonomy
                12.8.3.2.1. By Product
                 12.8.3.2.1.2. By Sales Channel
13. Europe HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032
    13.1. Introduction
    13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        13.3.1. By Country
            13.3.1.1. Germany
            13.3.1.2. Italy
            13.3.1.3. France
            13.3.1.4. U.K.
            13.3.1.5. Spain
            13.3.1.6. BENELUX
            13.3.1.7. Nordic Countries 
            13.3.1.8. Russia
            13.3.1.9. Rest of Europe
        13.3.2. By Product
        13.3.3. By Sales Channel
    13.4. Market Attractiveness Analysis
        13.4.1. By Country
        13.4.2. By Product
        13.4.3. By Sales Channel
    13.5. Market Trends
    13.6. Key Market Participants - Intensity Mapping
    13.7. Drivers and Restraints - Impact Analysis
    13.8. Country Level Analysis & Forecast
        13.8.1. Germany HIV Antivirals Market Analysis
            13.8.1.1. Introduction
            13.8.1.2. Market Analysis and Forecast by Market Taxonomy
                13.8.1.2.1. By Product
                13.8.1.2.2. By Sales Channel
        13.8.2. Italy HIV Antivirals Market Analysis
            13.8.2.1. Introduction
            13.8.2.2. Market Analysis and Forecast by Market Taxonomy
                13.8.2.2.1. By Product
                13.8.2.2.2. By Sales Channel
        13.8.3. France HIV Antivirals Market Analysis
            13.8.3.1. Introduction
            13.8.3.2. Market Analysis and Forecast by Market Taxonomy
                13.8.3.2.1. By Product
                13.8.3.2.2. By Sales Channel
        13.8.4. U.K. HIV Antivirals Market Analysis
            13.8.4.1. Introduction
            13.8.4.2. Market Analysis and Forecast by Market Taxonomy
                13.8.4.2.1. By Product
                13.8.4.2.2. By Sales Channel
        13.8.5. Spain HIV Antivirals Market Analysis
            13.8.5.1. Introduction
            13.8.5.2. Market Analysis and Forecast by Market Taxonomy
                13.8.5.2.1. By Product
                13.8.5.2.2. By Sales Channel
        13.8.6. BENELUX HIV Antivirals Market Analysis
            13.8.6.1. Introduction
            13.8.6.2. Market Analysis and Forecast by Market Taxonomy
                13.8.6.2.1. By Product
                13.8.6.2.2. By Sales Channel
        13.8.7. Nordic Countries HIV Antivirals Market Analysis
            13.8.7.1. Introduction
            13.8.7.2. Market Analysis and Forecast by Market Taxonomy
                13.8.7.2.1. By Product
                13.8.7.2.2. By Sales Channel
        13.8.8. Russia HIV Antivirals Market Analysis
            13.8.8.1. Introduction
            13.8.8.2. Market Analysis and Forecast by Market Taxonomy
                13.8.8.2.1. By Product
                13.8.8.2.2. By Sales Channel
14. East Asia HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032
    14.1. Introduction
    14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        14.3.1. By Country
            14.3.1.1. China
            14.3.1.2. Japan
            14.3.1.3. South Korea
        14.3.2. By Product
        14.3.3. By Sales Channel
    14.4. Market Attractiveness Analysis
        14.4.1. By Country
        14.4.2. By Product
        14.4.3. By Sales Channel
    14.5. Market Trends
    14.6. Key Market Participants - Intensity Mapping
    14.7. Drivers and Restraints - Impact Analysis
    14.8. Country Level Analysis & Forecast
        14.8.1. China HIV Antivirals Market Analysis
            14.8.1.1. Introduction
            14.8.1.2. Market Analysis and Forecast by Market Taxonomy
                14.8.1.2.1. By Product
                14.8.1.2.2. By Sales Channel
        14.8.2. Japan HIV Antivirals Market Analysis
            14.8.2.1. Introduction
            14.8.2.2. Market Analysis and Forecast by Market Taxonomy
                14.8.2.2.1. By Product
                14.8.2.2.2. By Sales Channel
        14.8.3. South Korea HIV Antivirals Market Analysis
            14.8.3.1. Introduction
            14.8.3.2. Market Analysis and Forecast by Market Taxonomy
                14.8.3.2.1. By Product
                14.8.3.2.2. By Sales Channel
15. South Asia HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032
    15.1. Introduction
    15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        15.3.1. By Country
            15.3.1.1. India
            15.3.1.2. Indonesia
            15.3.1.3. Malaysia
            15.3.1.4. Philippines
            15.3.1.5. Thailand
            15.3.1.6. Vietnam
            15.3.1.7. Rest of South Asia
        15.3.2. By Product
        15.3.3. By Sales Channel
    15.4. Market Attractiveness Analysis
        15.4.1. By Country
        15.4.2. By Product
        15.4.3. By Sales Channel
    15.5. Market Trends
    15.6. Key Market Participants - Intensity Mapping
    15.7. Drivers and Restraints - Impact Analysis
    15.8. Country Level Analysis & Forecast
        15.8.1. India HIV Antivirals Market Analysis
            15.8.1.1. Introduction
            15.8.1.2. Market Analysis and Forecast by Market Taxonomy
                15.8.1.2.1. By Product
                15.8.1.2.2. By Sales Channel
        15.8.2. Indonesia HIV Antivirals Market Analysis
            15.8.2.1. Introduction
            15.8.2.2. Market Analysis and Forecast by Market Taxonomy
                15.8.2.2.1. By Product
                15.8.2.2.2. By Sales Channel
        15.8.3. Malaysia HIV Antivirals Market Analysis
            15.8.3.1. Introduction
            15.8.3.2. Market Analysis and Forecast by Market Taxonomy
                15.8.3.2.1. By Product
                15.8.3.2.2. By Sales Channel
        15.8.4. Philippines HIV Antivirals Market Analysis
            15.8.4.1. Introduction
            15.8.4.2. Market Analysis and Forecast by Market Taxonomy
                15.8.4.2.1. By Product
                15.8.4.2.2. By Sales Channel
        15.8.5. Thailand HIV Antivirals Market Analysis
            15.8.5.1. Introduction
            15.8.5.2. Market Analysis and Forecast by Market Taxonomy
                15.8.5.2.1. By Product
                15.8.5.2.2. By Sales Channel
        15.8.6. Vietnam HIV Antivirals Market Analysis
            15.8.6.1. Introduction
            15.8.6.2. Market Analysis and Forecast by Market Taxonomy
                15.8.6.2.1. By Product
                15.8.6.2.2. By Sales Channel
16. Oceania HIV Antivirals Market 2012-2021 and Forecast 2022-2032
    16.1. Introduction
    16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        16.3.1. By Country
            16.3.1.1. Australia
            16.3.1.2. New Zealand
        16.3.2. By Product
        16.3.3. By Sales Channel
    16.4. Market Attractiveness Analysis
        16.4.1. By Country
        16.4.2. By Product
        16.4.3. By Sales Channel
    16.5. Market Trends
    16.6. Key Market Participants - Intensity Mapping
    16.7. Drivers and Restraints - Impact Analysis
    16.8. Country Level Analysis & Forecast
        16.8.1. Australia HIV Antivirals Market Analysis
            16.8.1.1. Introduction
            16.8.1.2. Market Analysis and Forecast by Market Taxonomy
                16.8.1.2.1. By Product
                16.8.1.2.2. By Sales Channel
        16.8.2. New Zealand HIV Antivirals Market Analysis
            16.8.2.1. Introduction
            16.8.2.2. Market Analysis and Forecast by Market Taxonomy
                16.8.2.2.1. By Product
                16.8.2.2.2. By Sales Channel
17. Middle East and Africa (MEA) HIV Antivirals Market Analysis 2012–2021 and Forecast 2022–2032
    17.1. Introduction
    17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2012–2021
    17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022–2032
        17.3.1. By Country
            17.3.1.1. GCC Countries
            17.3.1.2. Israel
            17.3.1.3. Turkey
            17.3.1.4. South Africa 
            17.3.1.5. North Africa
            17.3.1.6. Rest of Middle East and Africa
        17.3.2. By Product
        17.3.3. By Sales Channel
    17.4. Market Attractiveness Analysis
        17.4.1. By Country
        17.4.2. By Product
        17.4.3. By Sales Channel
    17.5. Market Trends
    17.6. Key Market Participants - Intensity Mapping
    17.7. Drivers and Restraints - Impact Analysis
    17.8. Country Level Analysis & Forecast
        17.8.1. GCC Countries HIV Antivirals Market Analysis
            17.8.1.1. Introduction
            17.8.1.2. Market Analysis and Forecast by Market Taxonomy
                17.8.1.2.1. By Product
                17.8.1.2.2. By Sales Channel
        17.8.2. Israel HIV Antivirals Market Analysis
            17.8.2.1. Introduction
            17.8.2.2. Market Analysis and Forecast by Market Taxonomy
                17.8.2.2.1. By Product
                17.8.2.2.2. By Sales Channel
        17.8.3. Turkey HIV Antivirals Market Analysis
            17.8.3.1. Introduction
            17.8.3.2. Market Analysis and Forecast by Market Taxonomy
                17.8.3.2.1. By Product
                17.8.3.2.2. By Sales Channel
        17.8.4. South Africa HIV Antivirals Market Analysis
            17.8.4.1. Introduction
            17.8.4.2. Market Analysis and Forecast by Market Taxonomy
                17.8.4.2.1. By Product
                17.8.4.2.2. By Sales Channel
        17.8.5. North Africa HIV Antivirals Market Analysis
            17.8.5.1. Introduction
            17.8.5.2. Market Analysis and Forecast by Market Taxonomy
                17.8.5.2.1. By Product
                17.8.5.2.2. By Sales Channel
18. Market Structure Analysis
    18.1. Market Analysis by Tier of Companies
    18.2. Market Share Analysis of Top Players
    18.3. Market Concentration
    18.4. Market Presence Analysis
        18.4.1. Regional Footprint Analysis
        18.4.2. Channel Footprint Analysis
19. Competition Analysis
    19.1. Competition Dashboard
    19.2. Competition Benchmarking
    19.3. Competition Deep Dive 
        19.3.1. ViiV Healthcare
            19.3.1.1. Overview
            19.3.1.2. Product Portfolio
            19.3.1.3. Sales Footprint
            19.3.1.4. Key Developments
            19.3.1.5. SWOT Analysis
            19.3.1.6. Strategy Overview
                19.3.1.6.1. Marketing Strategies
                19.3.1.6.2. Channel Strategies
        19.3.2. Gilead Sciences, Inc.
            19.3.2.1. Overview
            19.3.2.2. Product Portfolio
            19.3.2.3. Sales Footprint
            19.3.2.4. Key Developments
            19.3.2.5. SWOT Analysis
            19.3.2.6. Strategy Overview
                19.3.2.6.1. Marketing Strategies
                19.3.2.6.2. Channel Strategies
        19.3.3. GlaxoSmithKline plc
            19.3.3.1. Overview
            19.3.3.2. Product Portfolio
            19.3.3.3. Sales Footprint
            19.3.3.4. Key Developments
            19.3.3.5. SWOT Analysis
            19.3.3.6. Strategy Overview
                19.3.3.6.1. Marketing Strategies
                19.3.3.6.2. Channel Strategies
        19.3.4. Merck & Co., Inc.
            19.3.4.1. Overview
            19.3.4.2. Product Portfolio
            19.3.4.3. Sales Footprint
            19.3.4.4. Key Developments
            19.3.4.5. SWOT Analysis
            19.3.4.6. Strategy Overview
                19.3.4.6.1. Marketing Strategies
                19.3.4.6.2. Channel Strategies
        19.3.5. Johnson & Johnson
            19.3.5.1. Overview
            19.3.5.2. Product Portfolio
            19.3.5.3. Sales Footprint
            19.3.5.4. Key Developments
            19.3.5.5. SWOT Analysis
            19.3.5.6. Strategy Overview
                19.3.5.6.1. Marketing Strategies
                19.3.5.6.2. Channel Strategies
        19.3.6. Genetech, Inc.
            19.3.6.1. Overview
            19.3.6.2. Product Portfolio
            19.3.6.3. Sales Footprint
            19.3.6.4. Key Developments
            19.3.6.5. SWOT Analysis
            19.3.6.6. Strategy Overview
                19.3.6.6.1. Marketing Strategies
                19.3.6.6.2. Channel Strategies
        19.3.7. Teva Pharmaceutical Industries Ltd.
            19.3.7.1. Overview
            19.3.7.2. Product Portfolio
            19.3.7.3. Sales Footprint
            19.3.7.4. Key Developments
            19.3.7.5. SWOT Analysis
            19.3.7.6. Strategy Overview
                19.3.7.6.1. Marketing Strategies
                19.3.7.6.2. Channel Strategies
        19.3.8. AbbVie
            19.3.8.1. Overview
            19.3.8.2. Product Portfolio
            19.3.8.3. Sales Footprint
            19.3.8.4. Key Developments
            19.3.8.5. SWOT Analysis
            19.3.8.6. Strategy Overview
                19.3.8.6.1. Marketing Strategies
                19.3.8.6.2. Channel Strategies
        19.3.9. Cipla
            19.3.9.1. Overview
            19.3.9.2. Product Portfolio
            19.3.9.3. Sales Footprint
            19.3.9.4. Key Developments
            19.3.9.5. SWOT Analysis
            19.3.9.6. Strategy Overview
                19.3.9.6.1. Marketing Strategies
                19.3.9.6.2. Channel Strategies
        19.3.10. Pfizer Inc.
            19.3.10.1. Overview
            19.3.10.2. Product Portfolio
            19.3.10.3. Sales Footprint
            19.3.10.4. Key Developments
            19.3.10.5. SWOT Analysis
            19.3.10.6. Strategy Overview
                19.3.10.6.1. Marketing Strategies
                19.3.10.6.2. Channel Strategies
        19.3.11. Mylan N.V.
            19.3.11.1. Overview
            19.3.11.2. Product Portfolio
            19.3.11.3. Sales Footprint
            19.3.11.4. Key Developments
            19.3.11.5. SWOT Analysis
            19.3.11.6. Strategy Overview
                19.3.11.6.1. Marketing Strategies
                19.3.11.6.2. Channel Strategies
        19.3.12. Bristol-Myers Squibb Company
            19.3.12.1. Overview
            19.3.12.2. Product Portfolio
            19.3.12.3. Sales Footprint
            19.3.12.4. Key Developments
            19.3.12.5. SWOT Analysis
            19.3.12.6. Strategy Overview
                19.3.12.6.1. Marketing Strategies
                19.3.12.6.2. Channel Strategies
        19.3.13. Boehringer Ingelheim International GmbH
            19.3.13.1. Overview
            19.3.13.2. Product Portfolio
            19.3.13.3. Sales Footprint
            19.3.13.4. Key Developments
            19.3.13.5. SWOT Analysis
            19.3.13.6. Strategy Overview
                19.3.13.6.1. Marketing Strategies
                19.3.13.6.2. Channel Strategies
        19.3.14. Macleods Pharmaceuticals Ltd
            19.3.14.1. Overview
            19.3.14.2. Product Portfolio
            19.3.14.3. Sales Footprint
            19.3.14.4. Key Developments
            19.3.14.5. SWOT Analysis
            19.3.14.6. Strategy Overview
                19.3.14.6.1. Marketing Strategies
                19.3.14.6.2. Channel Strategies
        19.3.15. Emcure Pharmaceuticals Limited
            19.3.15.1. Overview
            19.3.15.2. Product Portfolio
            19.3.15.3. Sales Footprint
            19.3.15.4. Key Developments
            19.3.15.5. SWOT Analysis
            19.3.15.6. Strategy Overview
                19.3.15.6.1. Marketing Strategies
                19.3.15.6.2. Channel Strategies
        19.3.16. Aspen Pharmacare Limited
            19.3.16.1. Overview
            19.3.16.2. Product Portfolio
            19.3.16.3. Sales Footprint
            19.3.16.4. Key Developments
            19.3.16.5. SWOT Analysis
            19.3.16.6. Strategy Overview
                19.3.16.6.1. Marketing Strategies
                19.3.16.6.2. Channel Strategies
        19.3.17. Lupin Ltd.
            19.3.17.1. Overview
            19.3.17.2. Product Portfolio
            19.3.17.3. Sales Footprint
            19.3.17.4. Key Developments
            19.3.17.5. SWOT Analysis
            19.3.17.6. Strategy Overview
                19.3.17.6.1. Marketing Strategies
                19.3.17.6.2. Channel Strategies
        19.3.18. Sun Pharmaceutical Industries Ltd.
            19.3.18.1. Overview
            19.3.18.2. Product Portfolio
            19.3.18.3. Sales Footprint
            19.3.18.4. Key Developments
            19.3.18.5. SWOT Analysis
            19.3.18.6. Strategy Overview
                19.3.18.6.1. Marketing Strategies
                19.3.18.6.2. Channel Strategies
        19.3.19. Theratechnologies Inc.
            19.3.19.1. Overview
            19.3.19.2. Product Portfolio
            19.3.19.3. Sales Footprint
            19.3.19.4. Key Developments
            19.3.19.5. SWOT Analysis
            19.3.19.6. Strategy Overview
                19.3.19.6.1. Marketing Strategies
                19.3.19.6.2. Channel Strategies
        19.3.20. Strides Arcolab Limited
            19.3.20.1. Overview
            19.3.20.2. Product Portfolio
            19.3.20.3. Sales Footprint
            19.3.20.4. Key Developments
            19.3.20.5. SWOT Analysis
            19.3.20.6. Strategy Overview
                19.3.20.6.1. Marketing Strategies
                19.3.20.6.2. Channel Strategies
        19.3.21. Hetero labs limited
            19.3.21.1. Overview
            19.3.21.2. Product Portfolio
            19.3.21.3. Sales Footprint
            19.3.21.4. Key Developments
            19.3.21.5. SWOT Analysis
            19.3.21.6. Strategy Overview
                19.3.21.6.1. Marketing Strategies
                19.3.21.6.2. Channel Strategies
        19.3.22. Laurus Laboratories Ltd
            19.3.22.1. Overview
            19.3.22.2. Product Portfolio
            19.3.22.3. Sales Footprint
            19.3.22.4. Key Developments
            19.3.22.5. SWOT Analysis
            19.3.22.6. Strategy Overview
                19.3.22.6.1. Marketing Strategies
                19.3.22.6.2. Channel Strategies
20. Assumptions and Acronyms Used
21. Research Methodology
Recommendations

Healthcare

HIV Diagnostics Market

August 2024

REP-GB-14678

380 pages

Healthcare

Infection Prevention Market

December 2023

REP-GB-13950

333 pages

Healthcare

Prophylactic HIV Drugs Market

July 2023

REP-GB-9582

250 pages

Healthcare

HIV/HBV/HCV Test Kits Market

March 2023

REP-GB-9814

304 pages

Explore Healthcare Insights

View Reports
Future Market Insights

HIV Antivirals Market

Schedule a Call